Home Cart Sign in  
Chemical Structure| 106635-80-7 Chemical Structure| 106635-80-7

Structure of Tafenoquine
CAS No.: 106635-80-7

Chemical Structure| 106635-80-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tafenoquine is an oral active antimalaria drug that is being investigated as a potential treatment for malaria, as well as for malaria prevention.

Synonyms: WR 238605

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tafenoquine

CAS No. :106635-80-7
Formula : C24H28F3N3O3
M.W : 463.49
SMILES Code : CC(NC1=C2N=C(OC)C=C(C)C2=C(OC3=CC=CC(C(F)(F)F)=C3)C(OC)=C1)CCCN
Synonyms :
WR 238605
MDL No. :MFCD00598712
InChI Key :LBHLFPGPEGDCJG-UHFFFAOYSA-N
Pubchem ID :115358

Safety of Tafenoquine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Vero E6 cells 2.5 µM and 5 µM 1 to 3 days To evaluate the inhibitory effect of TFQ on SARS-CoV-2 viral RNA production. The results showed that TFQ significantly repressed the yield of viral RNA in cell supernatant, with an inhibition rate of approximately 51.9% to 54% (2.5 μM TFQ) at 48 hours post infection. J Biol Chem. 2022 Mar;298(3):101658
HEK-293T cells 50 µM and 100 µM 18 hours To assess the inhibitory effect of TFQ on SARS-CoV-2 Mpro activity. The results demonstrated that TFQ significantly inhibited Mpro activity, leading to increased fluorescence protein expression. J Biol Chem. 2022 Mar;298(3):101658
Babesia rodhaini-infected RBCs 100 mM 2 hours To evaluate the effect of TAF-induced oxidative stress on Babesia rodhaini, results showed that H2O2 treatment led to a vacuole-like aberrant parasite phenotype similar to TAF treatment. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0020421
Babesia bovis-infected bovine red blood cells 0.1–100 µM 4 days Evaluate the in vitro activity of Tafenoquine alone or in combination with artesunate against Babesia bovis. Results showed an IC50 of 31 μM for Tafenoquine alone and 15 μM when combined with artesunate, indicating a 2-fold increase in activity. Parasit Vectors. 2020 Jul 20;13(1):362
Leishmania major promastigotes 0.5 to 20 µM 72 hours To evaluate the inhibitory effect of Tafenoquine on the proliferation of Leishmania major promastigotes, showing that Tafenoquine inhibited proliferation in a dose-dependent manner at micromolar range with an EC50 of 2.2 ± 0.2 μM. Antimicrob Agents Chemother. 2010 Dec;54(12):5344-51
Leishmania donovani promastigotes 0.5 to 20 µM 72 hours To evaluate the inhibitory effect of Tafenoquine on the proliferation of Leishmania donovani promastigotes, showing that Tafenoquine inhibited proliferation in a dose-dependent manner at micromolar range with an EC50 of 5.6 ± 1.0 μM. Antimicrob Agents Chemother. 2010 Dec;54(12):5344-51
Plasmodium cynomolgi K4A7 1,424 nM 96 hours Determination of IC50 of Tafenoquine against Plasmodium cynomolgi, showing IC50(96 h) of 1,424 nM, indicating schizontocidal activity. Antimicrob Agents Chemother. 2024 May 2;68(5):e0028024

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c female mice Babesia microti infection model Oral 10 mg/kg (base) Alternate days (days 4, 6, and 8 post-infection) Evaluate the in vivo efficacy of Tafenoquine alone or in combination with artesunate against Babesia microti infection. Results showed potent inhibition of parasite growth after the second dose, leading to undetectable parasitemia by microscopy at day 9 post-infection. However, PCR remained positive in most mice post-treatment. Parasit Vectors. 2020 Jul 20;13(1):362
BALB/c mice and SCID mice Babesia rodhaini infection model Oral 20 mg/kg Single dose To evaluate the therapeutic effect of TAF on Babesia rodhaini infection in immunocompetent and immunocompromised mice, results showed that TAF rapidly cleared acute infection but recurrence occurred in immunocompromised mice. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0020421
BALB/c mice Acute Babesia microti infection model Oral gavage 20 mg/kg Single dose To evaluate the plasma levels and therapeutic efficacy of Tafenoquine in mice infected with Babesia microti. Results showed that a single oral dose of 20 mg/kg Tafenoquine significantly suppressed parasitemia within 48 hours and reduced parasitemia to levels undetectable by microscopy within 72 hours. Pathogens. 2023 Aug 31;12(9):1113

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06575647 Malaria|Malaria, Vivax|Plasmod... More >>ium Vivax|Plasmodium Vivax Malaria Less << PHASE4 NOT_YET_RECRUITING 2025-12-31 Shoklo Malaria Research Unit (... More >>SMRU), Mae Sot, Tak Province, Thailand Less <<
NCT06478641 Persistent Babesiosis AVAILABLE - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.16mL

0.43mL

0.22mL

10.79mL

2.16mL

1.08mL

21.58mL

4.32mL

2.16mL

References

 

Historical Records

Categories